Thomas A Hope1,2,3, Charles Truillet4, Eric C Ehman5, Ali Afshar-Oromieh6, Rahul Aggarwal3,7, Charles J Ryan3,7, Peter R Carroll3,8, Eric J Small3,7, Michael J Evans4. 1. Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California michael.evans@ucsf.edu. 2. Department of Radiology, San Francisco VA Medical Center, San Francisco, California. 3. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. 4. Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California. 5. Department of Radiology, Mayo Clinic, Rochester, Minnesota. 6. Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. 7. Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California; and. 8. Department of Urology, University of California, San Francisco, San Francisco, California.
Abstract
The purpose of this work was to evaluate the effect of androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged using 68Ga-PSMA-11 PET in a mouse xenograft model and in a patient with castration-sensitive prostate cancer. METHODS: We imaged 3 groups of 4 mice bearing LNCaP-AR xenografts before and 7 d after treatment with ARN-509, orchiectomy, or control vehicle. Additionally, we imaged one patient with castration-sensitive prostate cancer before and 4 wk after treatment with androgen deprivation therapy (ADT). Uptake on pre- and posttreatment imaging was measured and compared. RESULTS: PSMA uptake increased 1.5- to 2.0-fold in the xenograft mouse model after treatment with both orchiectomy and ARN-509 but not with vehicle. Patient imaging demonstrated a 7-fold increase in PSMA uptake after the initiation of ADT. Thirteen of 22 lesions in the imaged patient were visualized on PSMA PET only after treatment with ADT. CONCLUSION: Inhibition of the AR can increase PSMA expression in prostate cancer metastases and increase the number of lesions visualized using PSMA PET. The effect seen in cell and animal models can be recapitulated in humans. A better understanding of the temporal changes in PSMA expression is needed to leverage this effect for both improved diagnosis and improved therapy.
The purpose of this work was to evaluate the effect of androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged using 68Ga-PSMA-11 PET in a mouse xenograft model and in a patient with castration-sensitive prostate cancer. METHODS: We imaged 3 groups of 4 mice bearing LNCaP-AR xenografts before and 7 d after treatment with ARN-509, orchiectomy, or control vehicle. Additionally, we imaged one patient with castration-sensitive prostate cancer before and 4 wk after treatment with androgen deprivation therapy (ADT). Uptake on pre- and posttreatment imaging was measured and compared. RESULTS:PSMA uptake increased 1.5- to 2.0-fold in the xenograft mouse model after treatment with both orchiectomy and ARN-509 but not with vehicle. Patient imaging demonstrated a 7-fold increase in PSMA uptake after the initiation of ADT. Thirteen of 22 lesions in the imaged patient were visualized on PSMA PET only after treatment with ADT. CONCLUSION: Inhibition of the AR can increase PSMA expression in prostate cancer metastases and increase the number of lesions visualized using PSMA PET. The effect seen in cell and animal models can be recapitulated in humans. A better understanding of the temporal changes in PSMA expression is needed to leverage this effect for both improved diagnosis and improved therapy.
Authors: Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-05-15 Impact factor: 9.236
Authors: J Seidenfeld; D J Samson; V Hasselblad; N Aronson; P C Albertsen; C L Bennett; T J Wilt Journal: Ann Intern Med Date: 2000-04-04 Impact factor: 25.391
Authors: S Hijazi; B Meller; C Leitsmann; A Strauss; J Meller; C O Ritter; J Lotz; H-U Schildhaus; L Trojan; C O Sahlmann Journal: Prostate Date: 2015-09-10 Impact factor: 4.104
Authors: G L Wright; B M Grob; C Haley; K Grossman; K Newhall; D Petrylak; J Troyer; A Konchuba; P F Schellhammer; R Moriarty Journal: Urology Date: 1996-08 Impact factor: 2.649
Authors: Joseph R Osborne; Naveed H Akhtar; Shankar Vallabhajosula; Alok Anand; Kofi Deh; Scott T Tagawa Journal: Urol Oncol Date: 2012-05-31 Impact factor: 3.498
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236
Authors: Milan Grkovski; Karem Gharzeddine; Peter Sawan; Heiko Schöder; Laure Michaud; Wolfgang A Weber; John L Humm Journal: J Nucl Med Date: 2018-04-06 Impact factor: 10.057
Authors: Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Johanna Zörgiebel; Sophie M Schneefeld; Almut C A Walte; Katja Hueper; Christoph A von Klot; Christoph Henkenberens; Hans Christiansen; James T Thackeray; Tobias L Ross; Frank M Bengel Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-07 Impact factor: 9.236
Authors: Simona Malaspina; Ugo De Giorgi; Jukka Kemppainen; Angelo Del Sole; Giovanni Paganelli Journal: Radiol Med Date: 2018-08-16 Impact factor: 3.469
Authors: Thomas A Hope; Ali Afshar-Oromieh; Matthias Eiber; Louise Emmett; Wolfgang P Fendler; Courtney Lawhn-Heath; Steven P Rowe Journal: AJR Am J Roentgenol Date: 2018-06-27 Impact factor: 3.959
Authors: Sofia Vaz; Boris Hadaschik; Michael Gabriel; Ken Herrmann; Matthias Eiber; Durval Costa Journal: Eur J Nucl Med Mol Imaging Date: 2020-01 Impact factor: 9.236
Authors: Bernard H E Jansen; Gem M Kramer; Matthijs C F Cysouw; Maqsood M Yaqub; Bart de Keizer; Jules Lavalaye; Jan Booij; Hebert Alberto Vargas; Michael J Morris; André N Vis; Reindert J A van Moorselaar; Otto S Hoekstra; Ronald Boellaard; Daniela E Oprea-Lager Journal: J Nucl Med Date: 2019-01-10 Impact factor: 10.057